PR509
/ Yakult Honsha, Proacta
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 04, 2011
US, Japanese to trial NZ lung cancer drug
(Herald)
- Japanese and American companies plan to commission clinical trials of a promising lung cancer drug PR610 developed in New Zealand; It is being picked up for clinical development under a deal between Japanese pharmaceutical company Yakult Honsha and American biotechnology company Proacta; PR610 & PR509 have been targeted for development in NSCLC that is resistant to established treatments
Novel therapy • Non Small Cell Lung Cancer
1 to 1
Of
1
Go to page
1